Canadian data is current through March 2018. All of the data comes from Health Canada, except for the categories Manufacturer Parent Company and Product Classification.
The Parent Company and the Product Classification were added by ICIJ.
The parent company information is based on 2017 public records. The device classification information comes from FDA’s Product Classification by Review Panel, based on matches of recall data from the U.S. and Canada.
데이터 추가 비고
원인
Following an assessment of etest teicoplanin with staphylococcus spp. it has been observed that even though the mic essential agreement at +/- 1 dilution is les than 95% between etest tp256 and the reference method agar dilution (ad) for staphylococcus spp. an underestimation of mic values by at least 1 dilution has been observed for coagulase negative staphylococci (cons). this underestimation leads to a risk of false susceptible results linked in particular to the lack of an intermediate category interpretation if eucast breakpoints are applied for this antibiotic. during the study the false susceptible rate observed was 37.5% for cons where strains with an mic at 8 mg/ml by the reference method (resistant) can be found susceptible by etest teicoplanin.